Summary & Overview

CPT 0303U: Hypoxic BioChip Adhesion Assay for Sickle Cell Disease

Headline: New CPT code 0303U designates a proprietary lab test for measuring red blood cell adhesion under low-oxygen conditions, supporting sickle cell disease therapy evaluation.

Lead: CPT code 0303U identifies a Proprietary Laboratory Analyses (PLA) test, Hypoxic BioChip Adhesion from BioChip Labs™, which assesses red blood cell adhesion to vascular lining molecules under reduced oxygen using a microfluidic biochip. The test provides targeted biologic data that can inform therapeutic evaluation in sickle cell disease (SCD).

Why it matters: As precision diagnostics expand, PLA codes like 0303U capture manufacturer- or lab-specific assays that offer novel physiologic insights. National payers are increasingly evaluating coverage and payment approaches for such unique diagnostics due to their potential impact on treatment selection and clinical trial enrollment for rare and complex conditions like SCD.

Payers covered: Analysis includes major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

What readers will learn: This publication explains what CPT code 0303U represents, its clinical context in SCD assessment, typical laboratory service settings, and which national payers are considered in the analysis. It also summarizes available benchmarks, policy considerations for PLA codes, and the clinical implications of lab-based hypoxic adhesion testing. Data not available in the input will be identified as such where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0303UCPTProprietary Laboratory Analysessickle cell diseasemicrofluidic assayhypoxic adhesionlaboratory diagnosticsprecision medicine

Billing Code Overview

CPT code 0303U is a Proprietary Laboratory Analyses (PLA) code specific to a single laboratory test: Hypoxic BioChip Adhesion from BioChip Labs™. Using a whole blood specimen at reduced oxygen levels, the test evaluates adhesion of red blood cells (RBCs) to molecules found in the blood vessel lining using a microfluidic biochip. The analysis is intended to help evaluate potential therapies for sickle cell disease (SCD).

Service type: Laboratory diagnostic assay using a microfluidic biochip under hypoxic conditions to assess RBC adhesion
Typical site of service: Clinical laboratory or specialized reference laboratory setting where proprietary PLA testing is performed

Clinical & Coding Specifications

Clinical Context

A 28-year-old patient with known sickle cell disease (SCD) is enrolled in a clinical trial comparing new disease-modifying therapies. The clinician orders a hypoxic adhesion assay to evaluate red blood cell (RBC) adhesive properties under reduced oxygen tension using a microfluidic biochip. A whole blood specimen is collected in the outpatient infusion clinic or clinical research unit, handled per manufacturer instructions to preserve physiologic adhesion characteristics, and transported to BioChip Labs™ for the proprietary test. Results inform investigators and treating clinicians about RBC adhesion responses to investigational agents and may be used as a pharmacodynamic biomarker during therapy evaluation. Typical sites of service include hospital outpatient departments, academic medical center research laboratories, specialty hematology clinics, and reference laboratory settings that coordinate specimen transport and reporting. Specimen collection is performed by nursing or phlebotomy staff; the test is performed by the manufacturer/laboratory and reported using PLA code 0303U.

Coding Specifications

Modifier	Description	When to Use
`00`	Standard primary procedure	Not typically appended; indicates no modifier. Use per payer rules when no other modifier applies.

Taxonomy Code	Specialty	Notes
`2080P0202X`	Hematology	Specialists who manage SCD and order specialized adhesion assays for clinical trials or monitoring.
`207RH0000X`	Pediatric Hematology-Oncology	Pediatric specialists who coordinate testing for children with SCD in research or therapeutic monitoring.
`208D00000X`	Internal Medicine	Hospitalists or outpatient internists who manage adults with SCD and order specialized laboratory evaluations.
`207L00000X`	Pathology	Laboratory directors and pathologists who oversee specimen handling, test validation, and reporting in reference labs.
`363A00000X`	Clinical Laboratory Geneticists / Clinical Laboratory Scientists	Laboratory professionals responsible for performing or coordinating proprietary PLA testing and quality control.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D57.0`	Sickle-cell anemia with crisis	Common primary disease state prompting assessment of RBC adhesive behavior under hypoxia to evaluate disease severity and therapy response.
`D57.1`	Sickle-cell disease without crisis	Used when assessing baseline RBC adhesion characteristics in stable patients undergoing therapeutic monitoring or trial enrollment.
`D57.219`	Sickle-cell/Hb-C disease without crisis	Variant SCD genotype where adhesive properties may be evaluated to guide investigational therapy selection.
`D57.8`	Other sickle-cell disorders	Includes less common SCD genotypes where the hypoxic adhesion assay may provide phenotype-specific data.
`R79.9`	Abnormal findings on chemistry studies, unspecified	May be used adjunctively when reporting abnormal laboratory markers that prompt further specialized testing such as `0303U`.
`Z00.6`	Encounter for examination for normal comparison and control in clinical research program	Use when the test is performed as part of a clinical trial visit for baseline or follow-up assessments.
`Z51.0`	Encounter for antineoplastic chemotherapy and immunotherapy	Used if `0303U` is performed to monitor response to disease-modifying or investigational therapies administered during an oncology‑type treatment episode.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Commonly performed immediately prior to `0303U` to obtain the whole blood specimen required for the hypoxic biochip assay.
`99000`	Handling and/or conveyance of specimen for transfer from/off site laboratory	Used when the specimen requires special handling or transport to BioChip Labs™ or an external reference laboratory.
`80061`	Lipid panel (total cholesterol, HDL, LDL, triglycerides)	Example of concurrent laboratory monitoring often ordered in clinical trials; not specific but frequently co-ordered in comprehensive panels.
`81002`	Urinalysis, non-automated, without microscopy	Ancillary test commonly obtained in clinic visits for comprehensive assessment during trial visits.
`99070`	Supplies and materials (e.g., venipuncture supplies)	Used to bill for nonroutine supplies required for specialized specimen collection and preservation for `0303U`.